Autorizzazione alla conduzione dello Studio: “Phase II study of the combination of Ofatumumab and Ibrutinib followed by allogenic bone marrow transplant or consolidation for pretreated high risk patients with Chronic Lymphocytic Leukemia”. Numero EudraCT: 2015-000684-13. Codice: LLC1215.